The Quantellect read.As of Nov 19, 2026, 4 active firms cover LENZ Therapeutics Inc: 3 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $7.00 to $38.00 (about 5.4x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $23.50 sits 632% above the current $3.21. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees revenue growth near 30% this year and 203% next, consensus EPS building from about $-0.47 next quarter toward $-1.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy375%
Neutral125%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$23.50
+632.1% upside
Average target across 4 active firms as of Nov 19, 2026 vs $3.21 current
Highest Target$38.00
Average Target$23.50
Lowest Target$7.00
Detailed analyst forecasts for LENZ
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 3 of 4 active firms rate LENZ a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
LENZ EPS & revenue forecast
EPS · NEXT QUARTER
$-0.47
Range $-0.59 – $-0.39 · 3 analysts · -64% YoY
Next period, 3 analysts expect LENZ Therapeutics Inc to earn $-0.47 a share (range $-0.59 – $-0.39), versus $-1.32 a year earlier. Full-year consensus is $-4.16, growing to $-1.20 the year after.
REVENUE · NEXT QUARTER
$5.2M
Range $4.0M – $6.5M · 3 analysts · -41% YoY
Revenue is expected to reach $5.2M (range $4.0M – $6.5M), -41.0% year-over-year. Full-year consensus is $14.8M, rising to $32.6M next year.
Top analysts covering LENZ Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LENZ.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #155
Buy
$38.00+1083.8% to target
Overall win rate
49%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #160
Neutral
$7.00+118.1% to target
Overall win rate
47%
+ Follow
#3
Marc Goodman
Leerink Partners · Rank #251
Buy
$36.00+1021.5% to target
Overall win rate
46%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$10.00+211.5% to target
Overall win rate
38%
+ Follow
#5
Biren Amin
Piper Sandler
Neutral
$5.00+55.8% to target
Coverage
—
+ Follow
LENZ stock forecast FAQ
What is LENZ's average 12-month price target?+
The 4 active firms with a live target average $23.50 for LENZ Therapeutics Inc over the next 12 months, ranging from a $38.00 high to a $7.00 low, as of Nov 19, 2026.
Is LENZ stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for LENZ?+
The Street-high target is $38.00 (HC Wainwright & Co.), and the Street-low is $7.00 (Piper Sandler). The average of all 4 active-firm targets is $23.50.
How many active Wall Street firms cover LENZ?+
4 active firms have a recognized rating on LENZ Therapeutics Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering LENZ?+
Among analysts who currently cover LENZ, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #155). Their current call is Buy with a $38.00 target.
What is LENZ Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.47 per share (range $-0.59 – $-0.39) across 3 analysts. Full-year EPS is projected at $-4.16, rising to $-1.20 the following year.
How much revenue is LENZ Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.2M (range $4.0M – $6.5M). Full-year revenue is projected at $14.8M, growing to $32.6M next year.
Have analysts been upgrading or downgrading LENZ lately?+
As of Nov 19, 2026, 3 of 4 active firms rate LENZ a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LENZ calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.